The company acquired kSep Holdings, a single-use bioprocessing solutions company.
Sartorius Stedim Biotech (SSB) announced on July 6, 2016 that it will acquire kSep Holdings, a single-use bioprocessing solutions company based in Morrisville, North Carolina. The transaction valued kSep at approximately $28 million and will be closed by the end of July 2016. kSep markets single-use, fully automated centrifugation systems used for manufacturing biopharmaceuticals, such as vaccines, cell-based therapeutics, and monoclonal antibodies. kSep Systems is a spinoff from KBI Biopharma and was established in 2011.
Source: Sartorius Stedim Biotech
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.